Tata LPTA

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

Retrieved on: 
Saturday, June 10, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Antibiotics, Vaccine, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • Recent discovery of plasmid-mediated transferable colistin resistance genes have shown the ease with which resistance can spread in bacterial populations.
  • No cross-resistance with standard of care antibiotics was observed and the demonstrated Enterobacteriaceae-specificity versus broad-spectrum activity supports continued development for this class of antibiotics for the potential management and treatment of antimicrobial resistant pathogens.

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carba

Retrieved on: 
Wednesday, June 7, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Vaccine, Antibiotics, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • Antimicrobial resistance (AMR) has emerged as a significant threat for both patients and healthcare systems.
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • The compounds showed potent in vivo efficacy, especially in lung infection models as well as a promising in vitro and in vivo safety profile.